The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader

Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on the market in the coming years with the remarkable progress of an extensive pipeline, that premier late-stage pipeline is highlighted by its industry-leading neurological and cardiometabolic franchises. In late 2021, the company entered into a joint development and commercialization agreement to develop and commercialize eplonterson. Phase III studies are in the final stages and preparations are being made for commercialization. The critical hire of the Amyloidosis Medical Director was essential to Shay Bujanover’s Medical Affairs team, and The Chase Group is pleased to announce the placement of Veena Narayan, PhD, into the role. Dr. Narayan brings a depth of neuroscience education and experience to the team, including industry medical affairs strategy, launch, and co-commercialization expertise. If you seek a strong partnership with your executive search firm, we welcome the opportunity to work with you. Let us help you build your leadership team and experience the impact The Chase Group can have on your company’s success/growth. To learn more, email karen@chasegroup.com.
  • Categories: Biotechnology, Life Sciences, Pharmaceutical

Copyright © 1993-2024 The Chase Group. All Rights Reserved.